Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display

被引:21
作者
Mühle, C
Schulz-Drost, S
Khrenov, AV
Saenko, EL
Klinge, J
Schneider, H
机构
[1] Univ Erlangen Nurnberg, Childrens Hosp, Erlangen, Germany
[2] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Erlangen, Germany
[3] Amer Red Cross, Holland Lab, Rockville, MD USA
关键词
haemophilia; inhibitor; polyclonal antibodies; epitope mapping; phage display;
D O I
10.1160/TH03-07-0473
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clotting factor VIII (fVIII)-inhibitory antibodies represent a major problem in the treatment of haemophilia A. To understand the inactivation mechanisms and to pave the way towards modifications of recombinant clotting factors that reduce their immunogenicity, the exact localization of immunodominant epitopes is required. Here, a random peptide phage display library was employed to identify epitopes of polyclonal fVIII antibodies isolated from patient's plasma by affinity chromatography. FVIII binding specificity and inhibitory activity of the isolated fVIII antibodies were confirmed by ELISA and Bethesda assays. Phage selection on the individual samples yielded several phages which were displaced from binding to the respective antibody preparation by fVIII Their homology with amino acid motifs of human fVIII and immunoprecipitation results with radioactively labelled fVIII fragments suggested putative epitopes in the A1, A2 and C1 domains of fVIII for one and in the C2 domain for another patient. Synthetic peptides corresponding to the A2, C1 and C2 domain epitopes blocked antibody binding to fVIII and partially neutralized the inhibitory activity of the respective plasma in Bethesda assays. These results provide the proof of principle that random peptide libraries can be used for the mapping of epitopes in a polyclonal antibody preparation.
引用
收藏
页码:619 / 625
页数:7
相关论文
共 22 条
[1]   Phage display technology: clinical applications and recent innovations [J].
Azzazy, HME ;
Highsmith, WE .
CLINICAL BIOCHEMISTRY, 2002, 35 (06) :425-445
[2]   INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].
EHRENFORTH, S ;
KREUZ, W ;
SCHARRER, I ;
LINDE, R ;
FUNK, M ;
GUNGOR, T ;
KRACKHARDT, B ;
KORNHUBER, B .
LANCET, 1992, 339 (8793) :594-598
[3]   LOCALIZATION OF HUMAN FACTOR-FVIII INHIBITOR EPITOPES TO 2 POLYPEPTIDE FRAGMENTS [J].
FULCHER, CA ;
MAHONEY, SD ;
ROBERTS, JR ;
KASPER, CK ;
ZIMMERMAN, TS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (22) :7728-7732
[4]  
GRUPPO R, 1997, THROMB HAEMOST S, V162, pPD663
[5]   RESIDUES 484-508 CONTAIN A MAJOR DETERMINANT OF THE INHIBITORY EPITOPE IN THE A2 DOMAIN OF HUMAN FACTOR-VIII [J].
HEALEY, JF ;
LUBIN, IM ;
NAKAI, H ;
SAENKO, EL ;
HOYER, LW ;
SCANDELLA, D ;
LOLLAR, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14505-14509
[6]   A novel peptide, THALWHT, for the targeting of human airway epithelia [J].
Jost, PJ ;
Harbottle, RP ;
Knight, A ;
Miller, AD ;
Coutelle, C ;
Schneider, H .
FEBS LETTERS, 2001, 489 (2-3) :263-269
[7]   Pathophysiology of inhibitors to factor VIII in patients with haemophilia A [J].
Lacroix-Desmazes, S ;
Misra, N ;
Bayry, J ;
Artaud, C ;
Drayton, B ;
Kaveri, SV ;
Kazatchkine, MD .
HAEMOPHILIA, 2002, 8 (03) :273-279
[8]  
LUSHER JM, 2001, THROMB HAEMOST S, P2558
[9]   Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays [J].
Palmer, DS ;
Dudani, AK ;
Drouin, J ;
Ganz, PR .
VOX SANGUINIS, 1997, 72 (03) :148-161
[10]  
PITTMAN DD, 1993, BLOOD, V81, P2925